Cancer, infectious diseases drive point-of-care sensor adoption, says Lux Research
Sensor-based point-of-care medical devices will first make an impact in cancer care and infectious diseases, according to Lux Research.
Sensor-based point-of-care medical devices that can be used outside hospitals will first make an impact in cancer care and infectious diseases as rapid innovation, coupled with regulatory and insurer enthusiasm, drives adoption, according to Lux Research (Boston, MA).
Three major sensing technologies—imaging, optical molecular, and electrochemical—will be ready for strong adoption in oncology by 2030, while the more challenging infectious diseases will see similar adoption, but mainly of electrochemical sensors.
Lux Research analysts evaluated key point-of-care sensing technology families to predict likely adoption curves in key clinical indication spaces. Findings include:
- Over the next decade, optical coherence tomography (OCT) will emerge as the dominant imaging technology in cancer care as novel imaging modalities start disrupting large legacy systems such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET).
- Infectious diseases pose a big challenge for medical sensors, mainly on account of the sheer number of pathogens. Most approaches focus on in vitro diagnostics (IVD), with electrochemical sensors seeing the largest adoption due to high stability.
- Sensors for neurology are less mature than those for infectious diseases and cancer, but potentially represent the largest opportunity in the long run due to demographic and epidemiological trends. Electrodes and imaging will lead the pack for neurological uses.
The report, titled "Sensing (Is) the Future of Health Care: Technology Roadmapping Helps Find the Way," is part of the Lux Research BioElectronics Intelligence service.
Follow us on Twitter, 'like' us on Facebook, connect with us on Google+, and join our group on LinkedIn